Assembly Biosciences (NASDAQ:ASMB) Now Covered by HC Wainwright

Key Points

• HC Wainwright has reaffirmed a "Buy" rating for Assembly Biosciences, with a price target of $50.00, indicating a potential upside of 96.54% from its current stock price.
• During their last earnings report, Assembly Biosciences beat expectations with reported earnings of ($1.33) EPS against a consensus estimate of ($1.73), alongside revenue of $9.63 million.
• Several institutional investors have significantly increased their stakes in Assembly Biosciences, with 19.92% of the stock now owned by institutional investors and hedge funds.

HC Wainwright assumed coverage on shares of Assembly Biosciences (NASDAQ:ASMB - Free Report) in a research report released on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $50.00 target price on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Assembly Biosciences' Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.93) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at $0.87 EPS, Q4 2026 earnings at $0.86 EPS, FY2026 earnings at ($2.75) EPS, FY2027 earnings at $1.67 EPS, FY2028 earnings at ($1.34) EPS and FY2029 earnings at $3.07 EPS.

Assembly Biosciences Trading Up 1.1%

Assembly Biosciences stock traded up $0.28 during midday trading on Monday, reaching $26.93. The stock had a trading volume of 101,414 shares, compared to its average volume of 122,644. Assembly Biosciences has a 12 month low of $7.75 and a 12 month high of $27.17. The company has a market capitalization of $206.55 million, a P/E ratio of -4.83 and a beta of 0.64. The company has a fifty day moving average price of $19.80 and a two-hundred day moving average price of $14.76.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) EPS for the quarter, beating analysts' consensus estimates of ($1.73) by $0.40. The business had revenue of $9.63 million during the quarter, compared to analyst estimates of $5.30 million. Assembly Biosciences had a negative return on equity of 149.01% and a negative net margin of 117.20%. On average, equities research analysts predict that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its position in shares of Assembly Biosciences by 225.6% during the fourth quarter. JPMorgan Chase & Co. now owns 11,427 shares of the biopharmaceutical company's stock worth $180,000 after acquiring an additional 7,918 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Assembly Biosciences by 44.3% in the fourth quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company's stock worth $1,495,000 after buying an additional 29,087 shares during the period. Marshall Wace LLP increased its holdings in shares of Assembly Biosciences by 16.5% in the fourth quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company's stock worth $234,000 after buying an additional 2,098 shares during the period. B Group Inc. bought a new stake in shares of Assembly Biosciences in the fourth quarter worth about $799,000. Finally, Man Group plc bought a new stake in shares of Assembly Biosciences in the 4th quarter worth approximately $309,000. Hedge funds and other institutional investors own 19.92% of the company's stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.